There is now more research than ever into the benefits and risks of psychedelics—from traditional psychedelics such psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, to a countless and growing number of related natural and proprietary molecules. There are hundreds of new psychedelic companies, from ketamine clinics and psychedelic retreats to pharmaceutical companies and integration services.
After decades of stigma and misunderstanding, psychedelics are here to stay. Ketamine was approved by the FDA in 2019 for the treatment of major depression (Johnson & Johnson). FDA approval is also expected in 2021 for MDMA-assisted psychotherapy for PTSD (MAPS) and psilocybin-assisted psychotherapy for treatment-resistant depression (Compass Pathways).
The vast new field of psychedelic science and therapy, together with the ancillary services necessary for their safe and effective availability—treatment, integration, public and professional education, community support, research and clinical trials, retreats, and so much more—needs to expand with integrity as it grows to achieve its potential to heal minds and transform culture.
As you enter the legal psychedelic space, what will your impact be?
Much like the field of medical marijuana, psychedelics are breaking through into mainstream culture as therapeutic, scientific, and spiritual tools. As shown by the explosion of investor and philanthropic support of psychedelic research and therapy, the question is not if psychedelics will be incorporated into our legal, medical, and economic systems, but how.
For new psychedelic companies and for established brands wanting to keep up with shifts in public culture, the challenge is twofold: (1) to establish and maintain trust with donors, investors, and consumers who already recognize the potential of psychedelics; and (2) to remain accessible to those who remain (rightly after decades of misinformation) skeptical.
The current revolution in wellness and mental health is positioning psychedelics to be the first new approach to Western healthcare in decades. They’re bringing with them an entire new psychedelic industry. How can companies communicate about psychedelics in a way that reduces stigma, enhances trust, and remains in alignment with ethical values?
Integration Communications is committed to helping purpose-driven companies of all kinds expand their audience and enhance their brand with clarity, efficiency, and accountability as they work to bring psychedelics into our society.
Psychedelics are not a magic bullet—they must be used carefully, with intention, preparation, and ideally in community. In the same way, how you educate your audiences about psychedelics will affect not just their trust in your brand, but also what role psychedelics will play in their lives.
Let’s work together to make psychedelics legally and safely available to those who need them—with wisdom, integrity, and love.
Integration Communications was founded in 2020 by Brad Burge.
Brad earned his B.A. in Communication and Psychology from Stanford University in 2005 and his M.A. in Communication from the University of California, San Diego in 2009. He worked with MAPS from 2009 to 2020, where he engaged daily with journalists and media producers around the world to enhance public knowledge about psychedelic research, produced the largest psychedelic conference in history (Psychedelic Science 2017) while also helping develop and evolve MAPS' international brand and outreach strategy.
Brad is passionate about finding better ways for humans to work with the pharmaceutical and digital communications technologies of the 21st century. When he’s not plugged in, you’ll find him in the mountains, carrying a backpack, somewhere down a long trail.
Make your mark on the psychedelic renaissance.